No Comparison: FDA Draws Bright Line Between BLA, Biosimilar Pathways In Tbo-filgrastim Review
This article was originally published in Pharmaceutical Approvals Monthly
Teva’s tbo-filgrastim could have been the first review under FDA’s new biosimilars pathway, but Teva gambled that transplanting its successful European biosimilar G-CSF submission to the U.S. as a regular BLA had better odds. FDA used the review to make clear that it would be rigorous in distinguishing between 351(a) and 351(k) requirements.
You may also be interested in...
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.
An abbreviated pathway for follow-on biologics was one of the biggest issues for biotech investors in the legislative debate over health care reform. Two years after enactment, FDA is still waiting for the first application.
Teva is the first company to get FDA approval of a version of Amgen’s Neupogen; one biosimilar expert questions why Teva did not switch its BLA to a biosimilar application when that pathway became available.